Ebribafusp alfa

N/A

Report date: 2025/05/15 11:45:54

Base Information

Drug NameEbribafusp alfa
Drug Alias NameADX-097
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNephrosis, LipoidLupus Nephritis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesQ32 Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAkebia Therapeutics IncQ32 Bio Inc
Inactive CompaniesN/A
Active IndicationsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNephrosis, Lipoid
Inactive IndicationsLupus NephritisGlomerulonephritis, IGAKidney Diseases

Other Information

ATC CodeN/A
Related LinksN/A